A Phase I Study of Chemoradiotherapy Using Gemcitabine Plus Nab-paclitaxel for Unresectable Locally Advanced Pancreatic Adenocarcinoma
Phase of Trial: Phase I
Latest Information Update: 24 Nov 2017
Price : $35 *
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- 19 Nov 2017 Status changed from active, no longer recruiting to completed.
- 11 Nov 2017 Planned End Date changed from 1 Apr 2016 to 31 Dec 2017.
- 21 Jan 2017 Results (n=21), presented at the 2017 Gastrointestinal Cancers Symposium.